Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $301 | $268 | $282 | $289 |
| % Growth | 12.4% | -4.9% | -2.3% | – |
| Cost of Goods Sold | $124 | $104 | $106 | $108 |
| Gross Profit | $178 | $164 | $176 | $180 |
| % Margin | 59% | 61.1% | 62.4% | 62.5% |
| R&D Expenses | $21 | $19 | $20 | $23 |
| G&A Expenses | $85 | $82 | $78 | $74 |
| SG&A Expenses | $134 | $134 | $136 | $136 |
| Sales & Mktg Exp. | $49 | $51 | $57 | $62 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $155 | $153 | $156 | $159 |
| Operating Income | $23 | $11 | $20 | $21 |
| % Margin | 7.6% | 4% | 7.1% | 7.4% |
| Other Income/Exp. Net | $4 | $9 | $1 | $9 |
| Pre-Tax Income | $27 | $20 | $21 | $30 |
| Tax Expense | $8 | $6 | $8 | $8 |
| Net Income | $19 | $13 | $13 | $20 |
| % Margin | 6.3% | 4.9% | 4.7% | 7% |
| EPS | 231.72 | 161.12 | 166.83 | 252.73 |
| % Growth | 43.8% | -3.4% | -34% | – |
| EPS Diluted | 231.42 | 160.93 | 166.63 | 252.44 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $2 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $25 | $23 | $22 | $17 |
| EBITDA | $54 | $45 | $45 | $42 |
| % Margin | 18% | 16.6% | 16% | 14.5% |